InvestorsHub Logo
Followers 84
Posts 1928
Boards Moderated 0
Alias Born 03/05/2014

Re: Shane Chowdhury post# 10612

Tuesday, 02/14/2017 1:03:32 PM

Tuesday, February 14, 2017 1:03:32 PM

Post# of 233040
Here is a little perspective Shane.

We all know the private raises have a double negative on SP because of diluting and zero risk warrants. Up to this point it has been deemed the best option to raise $'s.

From my perspective all that matters is that Pro-140 makes it to the finish line meaning a buyout. The current SP is not an accurate measurement of our investment, however it is a constant reminder that causes one to question if they are missing something that is going to make for a bad ending. We all are fearful of making a bad decision. Pears does an over the top job illustrating that talk that can creep in to our minds.

Here is the bottom line...the macro view, and the question that we are all trying to measure. What will it take in terms of clinical data and FDA support to get the deep pockets of BP to step up and pull the trigger. A wise investor once told me BP does not move until it has to. BP is willing to pay substantially more for a sure thing than look stupid purchasing a drug that ends up in a ditch. So if you are GILD or GSK where is the tipping point? IMHO BTD Approval is where everything heats up. This will send a strong message to BP that the FDA is in our corner and Pro-140 approval is not a pipe dream but rather a forgone conclusion and sooner than later. BP will pull every move they can to bully CYDY and prolong the pathway to approval. We are a problem that they would like to see disappear. This is rough sledding when you are talking about reshuffling the deck on Billions of revenue.

The reason to remain calm is the data is going to continue to be strong and I believe the FDA see's it the same way. Can't make 5x - 20x without some pain and uncertainty.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News